Lataa...
Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma
BACKGROUND: Standard treatments for indolent non-Hodgkin lymphomas (iNHLs) are frequently toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed iNHL. The aim of this phase 2 trial (NCT00695786) was to evaluate the efficacy and...
Tallennettuna:
| Julkaisussa: | Lancet Oncol |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4370362/ https://ncbi.nlm.nih.gov/pubmed/25439689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70455-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|